This stuff in the body could control inflammation

Credit: CC0 Public Domain

In a new study, researchers have found a critical molecular mechanism behind autoimmune and inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis.

They discovered how the protein A20 prevents inflammation and autoimmunity, not through its enzymatic activities as has been proposed, but through a non-enzymatic mechanism.

These findings open up new possibilities for the treatment of inflammatory diseases.

The research was conducted by a team from the Flanders Institute for Biotechnology.

Inflammatory autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases, psoriasis, and multiple sclerosis are amongst the most common diseases.

Their prevalence has been rapidly expanding over the last few decades, which means that currently millions of patients are under constant treatment with anti-inflammatory drugs to keep their condition under control.

As an example, about 1% of the western population is affected by rheumatoid arthritis (RA), a chronic and progressive inflammatory disease of the joints that severely affects the patients’ quality of life.

The mechanisms that cause diseases such as RA need to be better understood in order to be able to develop new therapies to treat patients suffering from inflammatory pathologies.

In the study, the team examined the molecular signaling mechanism by which the protein A20 controls inflammatory reactions.

Their previous work had demonstrated that A20 acts as a strong anti-inflammatory mediator in many models of inflammatory disease.

The researchers show that the anti-inflammatory activity of A20 depends on the presence of a specific domain within the protein that is able to bind to ubiquitin, an important modification on other proteins.

This allows A20 to interfere with signaling pathways within the cell and as such prevent the activation of a cellular response that would normally result in inflammation and disease development.

The team says results are important from a scientific point of view since they help us understand how A20 prevents inflammatory reactions in the body’s cells.

However, this knowledge also has therapeutic implications and suggests that drugs based on that specific A20 domain could have strong anti-inflammatory activities.

Therefore, such drugs could be effective in the treatment of RA and various other inflammatory and autoimmune diseases.

The lead author of the study is Prof. Geert van Loo (VIB-UGent Center for Inflammation Research).

The study is published in the leading journal Nature Immunology.

Copyright © 2020 Knowridge Science Report. All rights reserved.